Net Income

A new, smaller implant for back surgery promises easier procedures for surgeons and lasting relief for patients by tackling the risk of reherniation.

A new growth medium aims to standardize stem cell production, addressing key regulatory and scalability challenges in the booming regenerative medicine market.

With online child abuse surging, legendary law enforcement expert Jim Cole joins Our Rescue to accelerate victim identification and fortify global partnerships.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

In a booming aesthetics market, one company is enlisting elite surgeons to architect the future of recovery, aiming to close a critical gap in patient care.

As markets grow top-heavy, Intech's math-driven ETFs gain traction by turning diversification and volatility into a systematic source of returns.

For the second year, First Financial is one of Gallup's best workplaces. We explore how this translates to a competitive edge and community impact.

For the eleventh straight year, Bitdefender's partner program earns CRN's top honor, a testament to its deep investment in partner success and innovation.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

The wholesale distributor is integrating its offline supply chain with a B2B digital platform, aiming for massive growth in China's tech-driven health market.

A new poll reveals overwhelming public opposition to a federal plan to stockpile glyphosate, fueled by billions in lawsuits and a retracted safety study.

With major retail deals at Walmart and Costco, AXIL aims to convince investors its hearing tech, not just haircare, can deliver profitable growth.

As Sera Prognostics preps its year-end report, investors watch to see if its groundbreaking preterm birth test can deliver financial health.

A reported 18% jump in chemicals M&A value masks a market driven by defense, not growth, as tariffs and portfolio pressures reshape the industry.

Data shows Achieve Life Sciences' drug helps smokers quit, even after multiple failed attempts with other drugs, as a critical FDA decision looms.

Social entertainment firm Newborn Town leverages proprietary AI to achieve massive profit growth, expand globally, and earn key capital market recognition.

As its stock stumbles, web-game leader CTW heads to the Roth Conference to prove its unique anime IP and HTML5 model can deliver long-term growth.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?